Systemic therapy for breast cancer is determined from the presence or absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor II (HER2) status as well as pathological factors such as nuclear grade and Ki-67 expression. The gene discussed is ESR1; the disease is breast carcinoma.